350 Index Name Paper ref. Name Paper ref. Mamchur, V Tue 354 Mammen, M Thu 069 Man, GSK Wed 290 Man, RYK FC15.2.6, YI.06, Thu 281, Wed 091, Mancini, F Thu 433 Mandia, R Tue 020 Mandoki Weitzner, JJ Thu 330 Mandrup, S FC18.1.4, Wed 447 Maneu, V Mon 472, Mon 473, Mon 477, Mon 481, Tue 478, Tue 422, Thu 407 Mangano, G Thu 433 Mangelsdorf, DJ FC18.1.3 Manjunatha, N FC01.4.6 Mann, D L FC06.4.1 Mannani, R Thu 392 Männistö, PT Wed 071, Mon 444, Mon 447, Mon 341 Mannoury La Cour, C Wed 072 Mannucci, C Thu 316 Manolopoulos, VG Tue 224, Mon 187 Manoury, B Tue 061 Manrique-Maldonado, G Thu 022, Thu 203 Mansell, S Tue 064 Mansoori, SD Mon 002 Mansour, D Tue 451 Mantegazza, M FC12.1.3 Manthey, L Wed 432, Tue 096 Manukyan, A Wed 205 Mao, H Wed 322 Maponga, C Tue 004 Marandykina, A Thu 023 Marathe, S W01.2.4 Marazioti, A FC15.3.6 Marazioti, Antonia Thu 202 Marbury, T Mon 205, Marchais-Oberwinkler, S Tue 442 Marchei, E Mon 375 Marchionni, N Mon 120 Marçola, M Thu 204 Mardirosian, Artin Mon 036 Marek, J Tue 448 Marichal-Cancino, BA Thu 022, Thu 203 Marie, S Mon 362 Marija, M Mon 347 Marijan, K Mon 347 Marimuthu, G Thu 327 Marinda, E Tue 001 Marjason, J Tue 312 Markholt, S Tue 359 Márki, A Mon 261 Markovic-Lipkovski, J Wed 103 Markovics, A W19.3, Mon 106, Mon 283 Marks, AR FC12.3.3 Markvardsen, LH Tue 161 Marques, AR Thu 202 Marques, E Wed 180, Tue 162 Marques, EB Wed 232 Marques, S Tue 162 Marquez, E-I Mon 471, Mon 149 Márquez, EI Wed 007, Mon 123 Marquié, J-C Mon 124 Marre, M Mon 161 Marrero Faz, E Thu 347 Marsch, R Thu 396 Marsh, A Mon 353, Mon 352 Marston, A Wed 375 Martel, F Mon 042, Mon 057 Martel, J-C Thu 024 Mårtensson, U Thu 047 Mårtensson-Lindblad, L Wed 092 Marthan, R Wed 293 Martikainen, JE Tue 363 Martikkala, E Wed 444 M, Roland FC09.2.2 M-Aurioles, E Tue 116 Martín-Campos, J Thu 042, Wed 059 Martínez Sánchez, G Thu 347 Martinez, C Mon 148, Wed 109 Martinez, G Mon 136 Martinez, GS Mon 038 Martinez, K Thu 037 Martinez, KL Thu 086 Martinez, MC Wed 216, Wed 196 Martínez, P Thu 249 Martinez-Caro, L Thu 235 Martínez-González, J W09.4 Martínez-Saénz, A Mon 411 Martini, L Wed 073 Martinkova, J Tue 125, Wed 017 Martinovic, M Thu 231, Wed 019, Wed 018, Thu 001 Martins, A Wed 131 Martins, AMC Thu 374, Wed 297 Martins, F Wed 140 Martins, VV Wed 339 Martiny, L FC11.5.6 Marton, Z Wed 197 Martos, J Thu 088 Maru, Y Thu 444 Maruo, T Mon 035 Marusic, S Wed 112 Maruyama, A Mon 253 Maruyama, I Thu 331 Mashinchian, O Thu 303 Mason, BJ FC14.2.4 Masri, B Wed 423 Massard, J W02.2.6 Masson, E Tue 495 Masson, I Mon 191 Mastrantonio, G Wed 003 Masubuchi, Y Wed 115 Masuda, S Tue 156, Tue 225 Masuda, T Wed 223 Mataji, A Mon 099 Matak, I Mon 096 Matchkov, V Tue 038, Wed 433 Mateos-Campos, R Tue 088, Tue 089 Matesanz, N Tue 134 Mathews, T Wed 076 Mathiasen, S Thu 026 Mathiassen, ON Mon 200 Mathie, AA FC03.3.6 Mathiesen, JM Thu 027 Mathison, Y Thu 205 Mathison, Y Mon 295, Wed 251, Thu 271 Mathur, M Tue 453, Tue 020, Wed 116
Name Paper ref. Name Paper ref. Mato, ID Mon 125 Matos, MG Mon 295, Tue 226, Wed 212, Thu 254 Matreja, P Mon 005 Matsabisa, G Wed 389 Matsabisa, MG Wed 390, Wed 391 Matschke, K Tue 012 Matsuda, M Thu 038 Matsuda, T Tue 360, Tue 060 Matsui, N Mon 253 Matsumoto, H Tue 432 Matsumoto, K FC16.3.3, Mon 386 Matsumoto, N Tue 273, Tue 337, Tue 483, Tue 492, Wed 117 Matsumoto, Y Tue 263 Matsumura, K Tue 162 Matsunaga, H Wed 413 Matsunami, M Tue 263, Tue 077 Matsuo, Y Thu 263 Matsuoka, T Tue 260, Tue 294 Matsuomoto, N Tue 336 Matsushima, S Mon 424 Matsushita, A Thu 099, Mon 461 Matsushita, K PL14 Matsuzaki, T Thu 344 Mattace Raso, G Thu 081 Mattheij, NJA Thu 208 Matthews, S Tue 309 Matuskova, Z Wed 118 Matwyshyn, G FC05.2.5, Wed 184 Matz, J Tue 303 Maulik, SK Thu 304 Maurel, D Wed 077 Maurice, P Thu 028 Maurizio, R Thu 400 Maussang, D Wed 086 Mavrakanas, T Tue 126, Thu 206 Mavri, J Mon 074 Maxwell, S FC01.3.7, Maxwell, SRJ FC01.1.3, W20.4 May, D W03.6 May, K Tue 039, Tue 131, Wed 119 Mayer, B PL24, Tue 227 Mayer, ME Mon 247 Mayer, P Tue 129 Mazella, J FC17.2.5 Mazzaglia, G FC04.1.6 Mazzon, E FC18.1.5, Mon 277, Mon 286, FC18.3.6 McArthur, K FC15.1.6 McArthur, S FC15.1.5 McCarthy, C FC08.3.2 McClymont, D Thu 029 McDougal, I Wed 032 McFadzean, I Tue 230 McField, R Tue 097, Tue 120 McGarth, J C W01.2.2 McGrath, J Thu 030 McGuire, JJ Wed 271 McGuire, J J Thu 207 McIntyre, P W03.7 McKown, R Thu 110 McLachlan, A FC13.2.6 McLaverty, M Tue 456, Tue 279 McLay, J Wed 137 McLay, JS Tue 109 McNally, G FC03.3.1 McNaughton, PA FC03.1.3 McPhaden, A Thu 272 McQuain, C Mon 264 Meana, JJ Wed 031, Thu 031, Thu 399 Mécs, Z Thu 307 Medard, Y Wed 011, FC10.1.5 Medina, A Wed 007 Medina, I Wed 265 Medina, P Thu 225 Medved, V Wed 398 Medvedeva, N Wed 283 Meena, S Wed 294 Meens, M Wed 037 Meens, MJPMT Thu 208 Meesarapee, B Tue 277, Thu 305 Megersa, TN Thu 032 Megson, I Mon 211 Megyeri, A Mon 150, Mon 167 Mehdipour, AR Thu 309 Mehla, J Mon 452, Mehmood, MH Wed 354 Mehnert, F FC04.2.7 Mehta, N FC09.5.7 Mei, Q Tue 286 Meier, SM FC11.3.2 Meiler, J FC11.3.2 Meili, S Thu 309 Meissner-Kirch, O Mon 037 Mejyr, S W35.4 Melcon de Dios, A Wed 109 Meli, R FC18.1.6, Thu 081 Mellor, I Thu 029 Melo, PA Wed 339 Melo, T Wed 318, Wed 319 Mendell, J Tue 228, Wed 122, Wed 121, Wed 120 Mendelson, J FC14.2.5, Mon 388, Wed 170 Mendes, AF Tue 257 Mendes, E Tue 086 Mendez-Cruz, AR Tue 150 Mendoza Hernandez, IC Mon 038 Mendoza Patiño, N Thu 330 Mendoza Rodríguez, Y Thu 425, Thu 424 Mendoza, Y Thu 394, Thu 395 Mendoza-Ramos, MI Tue 150 Menendez, C Tue 121, Wed 226, Thu 217, Thu 235 Menezes, G Tue 229 Menezes, R Wed 131 Meng, X Tue 117, Thu 306, Thu 369 Meng, Y Tue 035 Menghini, L Wed 329 Menna, A FC04.3.6 Menon, G Wed 006 Menon, P Tue 230 Menoyo, E Thu 177, Thu 178 Menzen, MH Tue 242, Wed 095 Mer, M Mon 308 Meræep, I Mon 048 Meraner, P FC12.5.4 Merino -Garcia, N Wed 344 Index 351
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297:
FC14 Addiction and doping: Neurobio
- Page 298 and 299:
FC15 Endothelium in health and dise
- Page 300 and 301:
FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor